Omnipaque 140 Generic Name & Formulations
Iohexol 302mg (equivalent to 140mg of organic iodine) per mL; soln; preservative-free.
Radiographic contrast medium.
Omnipaque 140 (50mL)—10; Omnipaque 180 (10mL)—10; Omnipaque 240 (10mL, 20mL, 50mL, 100mL)—10; Omnipaque 300 (10mL, 30mL, 50mL, 100mL, 125mL, 150mL)—10; Omnipaque 350 (50mL, 75mL, 100mL, 125mL, 150mL, 200mL)—10
Mechanism of Action
The iodine atoms in iohexol provide attenuation of X-rays in direct proportion to the concentration of iohexol. Since concentration changes over time, iohexol provides time-dependent image contrast which may assist in visualizing body structures.
Omnipaque 140 Indications
IV administration: in adults, for intra-arterial digital subtraction angiography of the head, neck, abdominal, renal and peripheral vessels.
Omnipaque 140 Dosage and Administration
Adults and Children
See full labeling for dosing based on procedure.
Omnipaque 140 Contraindications
Omnipaque 140 and 350: for intrathecal use. Omnipaque body cavity 240 and 300: for hysterosalpingography during pregnancy or suspected pregnancy, menstruation or when menstruation is imminent, within 6 months after termination of pregnancy, within 30 days after conization or curettage, when signs of infection are present in any portion of the genital tract including the external genitalia, and when reproductive tract neoplasia is known or suspected.
Omnipaque 140 Boxed Warnings
Risks with inadvertent intrathecal administration of Omnipaque 140 and 350 injection.
Omnipaque 140 Warnings/Precautions
Do not administer Omnipaque 140 and 350 intrathecally: severe reactions may occur (eg, death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, brain edema). Have emergency treatment and trained personnel readily available. Monitor for hypersensitivity reactions. Cardiovascular disease (monitor). Pheochromocytoma. Homozygous sickle cell disease. Homocystinuria: avoid angiocardiography. Hyperthyroidism. Thyroid dysfunction (esp. children 0–3yrs); monitor. Renal impairment or risk of (eg, diabetes, dehydration, multiple myeloma, CHF, advanced vascular disease). History of severe cutaneous reaction: avoid. Ensure adequate hydration. Avoid extravasation (esp. in arterial or venous disease). Elderly. Pregnancy. Nursing mothers: consider interrupting; pump/discard breast milk for 10hrs after administration.
Omnipaque 140 Pharmacokinetics
<1% of orally administered iohexol is absorbed from the normal gastrointestinal tract.
Plasma volume of distribution: 559 (350–849) mL/kg.
Renal. Peak urine concentration occurs in the first hour after injection.
Apparent first-order terminal half-life: 12.6 hours.
Total body clearance: 131 (98–165) mL/min.
Omnipaque 140 Interactions
Concomitant drugs that lower seizure threshold (eg, phenothiazines): not recommended with intrathecal use. Discontinue metformin at time of, or prior to Omnipaque in patients with eGFR 30–60mL/min/1.73m2, history of hepatic impairment, alcoholism, heart failure, or will be given intra-arterial contrast; reevaluate eGFR 48hrs after procedure and restart metformin if renally stable. Increased risk of kidney injury with concomitant nephrotoxic drugs or diuretics. Discontinue CNS active drugs (eg, MAOIs, tricyclics, CNS stimulants, analeptics, tranquilizers, antipsychotics) ≥48hrs before myelography and for ≥24hrs post-procedure. Caution with beta-blockers. May interfere with thyroid uptake of radioactive iodine and decrease efficacy in thyroid carcinoma for up to 6–8 weeks. May reduce iodine-binding capacity of thyroid tissue for up to 2 weeks.
Omnipaque 140 Adverse Reactions
Intrathecal: headache, backache, neckache, stiffness, neuralgia, nausea, vomiting, dizziness. IV: inj site reactions, pain, arrhythmias, angina/chest pain, hypotension, vertigo, vision abnormalities, headache, taste perversion, nausea; severe skin reactions (eg, SJS, TEN, AGEP, DRESS). Oral: diarrhea, nausea, vomiting, abdominal pain, flatulence, headache; children: also, fever, hypotension, urticaria. Body cavities: pain, swelling, heat sensation. Angiocardiography: thromboembolism. Hypersensitivity reactions, acute kidney injury, cardiovascular reactions.
Omnipaque 140 Clinical Trials
Omnipaque 140 Note
Omnipaque 140 Patient Counseling